Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nicolas BoisselClaude Preudhomme

Abstract

Recently, whole-genome sequencing in acute myeloid leukemia (AML) identified recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations (IDH1m), previously reported to be involved in gliomas as well as IDH2 mutations (IDH2m). The prognosis of both IDH1m and IDH2m in AML remains unclear. The prevalence and the prognostic impact of R132 IDH1 and R172 IDH2 mutations were evaluated in a cohort of 520 adults with AML homogeneously treated in the French Acute Leukemia French Association (ALFA) -9801 and -9802 trials. The prevalence of IDH1m and IDH2m was 9.6% and 3.0%, respectively, mostly associated with normal cytogenetics (CN). In patients with CN-AML, IDH1m were associated with NPM1m (P = .008), but exclusive of CEBPAm (P = .03). In contrary, no other mutations were detected in IDH2m patients. In CN-AML patients, IDH1m were found in 19% of favorable genotype ([NPM1m or CEBPAm] without fms-related tyrosine kinase 3 [FLT3] internal tandem duplication [ITD]) and were associated with a higher risk of relapse (RR) and a shorter overall survival (OS). Favorable genotype in CN-AML could thus be defined by the association of NPM1m or CEBPAm with neither FLT3-ITD nor IDH1m. In IDH2m CN-AML patients, we observed a higher risk of in...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Oct 16, 1999·The Journal of Biological Chemistry·B V Geisbrecht, S J Gould
Nov 21, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·M Christiane Brahimi-HornJacques Pouysségur
Oct 22, 2008·Journal of Neuro-oncology·Mahdi AghiliElham Rafiee
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Sep 10, 2009·Cancer Science·Hiroko Ohgaki, Paul Kleihues
Oct 27, 2009·Biochemical and Biophysical Research Communications·Guilan JinHayato Miyachi
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cecile PautasSylvie Castaigne
Jan 29, 2010·The New England Journal of Medicine·Anthony Green, Philip Beer

❮ Previous
Next ❯

Citations

Dec 3, 2010·Frontiers of Medicine in China·Felicitas Thol, Arnold Ganser
Sep 8, 2012·Current Treatment Options in Oncology·Adriana Olar, Kenneth D Aldape
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Oct 2, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jiang-Han WangSai-Juan Chen
Jul 20, 2012·Genetic Testing and Molecular Biomarkers·Yiqun ZhangJianxiang Wang
Feb 6, 2013·Current Opinion in Hematology·Mathijs A Sanders, Peter J M Valk
Dec 17, 2011·Applied Immunohistochemistry & Molecular Morphology : AIMM·Richard ByersScott J Rodig
Dec 14, 2011·The Cancer Journal·Timothy A Graubert, Elaine R Mardis
Aug 22, 2012·Acta Haematologica·Milos KuzmanovicMilica Colovic
Sep 4, 2013·The Journal of Clinical Investigation·Anna Sophia McKenney, Ross L Levine
Sep 16, 2011·Journal of Hematology & Oncology·Shinichiro Takahashi
Apr 30, 2011·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Nadia A AtaiCornelis J F Van Noorden
Aug 21, 2013·Annals of Hematology·Saquib AshrafFrancesco Lo-Coco
Oct 15, 2014·Seminars in Hematology·Matias SanchezRaajit Rampal
Jun 2, 2015·Expert Opinion on Therapeutic Targets·Angela NebbiosoLucia Altucci
Jan 21, 2016·Expert Review of Hematology·Hsin-An Hou, Hwei-Fang Tien
Mar 6, 2013·Surgical Pathology Clinics·Craig Horbinski
Aug 25, 2012·Human Pathology·Dinesh RakhejaWeina Chen
Dec 27, 2011·Annals of Diagnostic Pathology·Adriana OlarGregory N Fuller
Nov 19, 2011·Hematology/oncology Clinics of North America·Omar Abdel-WahabRoss L Levine
Aug 29, 2013·Protein & Cell·Grace L PeloquinAmir T Fathi
Jul 16, 2014·Neoplasia : an International Journal for Oncology Research·Hsiao-Wen KaoLee-Yung Shih
Feb 15, 2011·Leukemia Research·Yiqun ZhangJianxiang Wang
Dec 7, 2010·Brain Pathology·Andreas von DeimlingChristian Hartmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.